-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Drug Administration shows that Jiangsu Wu Traditional Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory's injection of Esso melazole sodium was approved. according to
meters of intranet data, in 2019 China's public medical institutions terminal Esomerazole (Esso melanzoa) injection sales exceeded 3 billion yuan, of which AstraZeneone market share of 51.48 percent, ranked first.
data show that the product is a new generation of clinical acid suppressor products, with fast, powerful, long-lasting, small individual differences and so on, used when oral therapy is not applicable, gastroesophageal reflow disease (GERD) alternative therapy;
In recent years, China's public medical institutions terminal Esomerazo (Esso meprazole) injection sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Minet data show that in recent years in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Esomerazole injections are growing at a rate of more than 10%, with sales exceeding 3 billion yuan in 2019, with AstraZeneone leading with 51.48 percent of the market, followed by Zhengda Tianqing Pharmaceutical Group with 34.14 percent.
source: One-click retrieval is worth noting that AstraZeneta's market share has declined rapidly in recent years, from its exclusive market in 2015 to 72.95 per cent in 2017 and to 51.48 per cent in 2019.
in terms of consistency evaluation, the product has not yet been approved by enterprises.
source: official website of the State Drug Administration, Mi net database.